GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 180 Life Sciences Corp (NAS:ATNF) » Definitions » Degree of Financial Leverage

180 Life Sciences (180 Life Sciences) Degree of Financial Leverage : 1.50 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is 180 Life Sciences Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). 180 Life Sciences's Degree of Financial Leverage for the quarter that ended in Mar. 2024 was 1.50. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for 180 Life Sciences's Degree of Financial Leverage or its related term are showing as below:

ATNF's Degree of Financial Leverage is ranked worse than
78.92% of 1499 companies
in the Biotechnology industry
Industry Median: 0.96 vs ATNF: 1.50

180 Life Sciences Degree of Financial Leverage Historical Data

The historical data trend for 180 Life Sciences's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

180 Life Sciences Degree of Financial Leverage Chart

180 Life Sciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Degree of Financial Leverage
- 1.17 0.56 -0.09 1.88

180 Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 1.21 0.54 1.88 1.50

Competitive Comparison of 180 Life Sciences's Degree of Financial Leverage

For the Biotechnology subindustry, 180 Life Sciences's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


180 Life Sciences's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 180 Life Sciences's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where 180 Life Sciences's Degree of Financial Leverage falls into.



180 Life Sciences Degree of Financial Leverage Calculation

180 Life Sciences's Degree of Financial Leverage for the quarter that ended in Mar. 2024 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -41.785 (Mar. 2024) / -406.77 (Mar. 2023) - 1 )/( -18.542 (Mar. 2024) / -45.96 (Mar. 2023) - 1 )
=-0.8973/-0.5966
=1.50***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


180 Life Sciences  (NAS:ATNF) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


180 Life Sciences Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of 180 Life Sciences's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


180 Life Sciences (180 Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, CA, USA, 94306
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics.
Executives
James N. Woody director, officer: Chief Executive Officer C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Marc Feldmann director 5 DURHAM TERRACE, LONDON X0 W25PB
Lawrence Steinman director 10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Mcgovern Jr. Donald A. director C/O CARS.COM, 300 S. RIVERSIDE PLAZA, SUITE 1000, CHICAGO IL 60606
Quan Anh Vu officer: COO / Chief Business Officer 22616 ERWIN STREET, WOODLAND HILLS CA 91367
Ozan Pamir officer: Interim CFO 2443 FILLMORE ST #380-17649, SAN FRANCISCO CA 94115
Pamela G Marrone director C/O MARRONE BIO INNOVATIONS, INC., 2121 SECOND STREET, A-107, DAVIS CA 95618
Teresa Deluca director 40 BURTON HILLS BOULEVARD, SUITE 500, NASHVILLE TN 37215
Russell T Ray director 2525 DUPONT DR, IRVINE CA 92612
Knuettel Ii Francis director 205 NEWBURY ST, SUITE 204, FRAMINGHAM MA 01701
Marlene Krauss director, 10 percent owner, officer: Chief Executive Officer C/O KBL HEALTHCARE INC, 645 MADISON AVE, NEW YORK NY 10022
Lawrence Marshall Gold director 830 MENLO AVENUE, SUITE 100, MENLO PARK CA 94025
Jonathan B. Rothbard officer: Chief Scientific Officer 501 BEALE STREET, UNIT 8D, SAN FRANCISCO CA 94105
Shoshana Shendelman director C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Richard W Barker director 290 COMMONWEALTH AVENUE #17, BOSTON MA 02115

180 Life Sciences (180 Life Sciences) Headlines

From GuruFocus

180 Life Sciences Announces Presentation at the Gordon Conference

By sperokesalga sperokesalga 02-27-2023